SLU-PP-332 + BAM15: Research Guide

Quick Reference Card

Overview

The SLU-PP-332 + BAM15 blend is a marketed research combination built from two separate metabolic stories. SLU-PP-332 is presented in the literature as a synthetic pan-ERR agonist that can trigger exercise-like transcriptional programs in mouse skeletal muscle [2][3]. BAM15 is presented as a mitochondrial protonophore that can lower mitochondrial coupling efficiency and alter energy expenditure in mouse models [5][6][7].

That combination can sound coherent, but the blend has not been validated as its own pharmacology package. The available evidence supports component-level mechanisms in animal or cell models. It does not support a combined human protocol, a combined human safety margin, or a product-class assumption that all fixed-ratio SLU/BAM15 blends mean the same thing.

The most practical reading is simple: a blend record is a product format, not a clinical evidence tier. It tells the reader that two compounds were packaged together at a stated ratio. It does not prove the ratio is optimal, safe, or clinically meaningful.

Component Identity

Neither compound is a peptide in the ordinary biochemical sense, even though both may appear in peptide-market catalogs.

Mechanism

SLU-PP-332 acts through the estrogen-related receptor family, especially ERRα in the published exercise-response work [2]. ERRs are nuclear receptors involved in oxidative metabolism and mitochondrial gene programs. They are distinct from estrogen receptors, but that distinction does not prove endocrine safety in humans.

BAM15 works through mitochondrial uncoupling. It dissipates the proton gradient across the inner mitochondrial membrane, which can increase fuel oxidation and heat/energy dissipation in preclinical models [5][6][7]. This mechanism is pharmacologically sensitive because excessive uncoupling can narrow the gap between an experimental metabolic effect and a safety problem.

Putting the two together is mechanistically plausible as a research idea: one component changes transcriptional metabolic programming, and the other changes mitochondrial coupling efficiency. The problem is that plausibility is not the same as a tested combined exposure. A fixed tablet or capsule cannot reveal whether an observed effect comes from ERR agonism, uncoupling, both together, or an uncontrolled interaction between them.

Pathway Visualization Image

Caption: This refreshed graphic treats the blend as a fixed-ratio product format, not a tested synergy: component mechanisms are preclinical and no combined human pharmacokinetics, trial, safety margin or validated protocol was found [2][3][5][6][7][8][9][10][11].

Evidence And Pharmacokinetic Limits

SLU-PP-332 has no published human pharmacokinetic profile in the evidence reviewed here. Billon et al. used it as an in vivo chemical tool in mice and reported mouse dosing contexts, including 50 mg/kg intraperitoneal use [2][3]. Those studies support target biology and mouse outcomes, not human dose selection.

BAM15 has stronger mouse PK detail than SLU-PP-332. Alexopoulos et al. reported about 67% oral bioavailability and a 1.7-hour mouse half-life in their BAM15 work, while diet admixture maintained mouse exposures used in obesity experiments [6]. Axelrod et al. reported dietary exposure of about 85 mg/kg/day in a high-fat-diet mouse model and acute intraperitoneal injection experiments [7]. Those measurements are still component-only animal data.

No source found in this refresh reported combined SLU-PP-332+BAM15 human PK, combined dose escalation, combined toxicity, or a clinical endpoint. That absence matters because the two components would need separate absorption, distribution, metabolism, toxicity, and interaction assessment before a fixed ratio could be interpreted as anything more than a product format.

Fixed-Ratio Interpretation

The most common blend misunderstanding is treating the label as if each component has the same amount. It usually does not. A 250 mcg + 50 mcg listing means 250 mcg of one component plus 50 mcg of the other component. The combined active mass is 300 mcg before excipients, and the ratio is 5:1.

Other pages use very different ratios. Pure Peptides Canada lists 25 mg BAM15 + 100 mcg SLU-PP-332 and 35 mg BAM15 + 250 mcg SLU-PP-332 tablet options [11]. Those are not small variations on the same product logic. They put far more mass on the BAM15 side than a 250 mcg + 50 mcg page does.

That is why a blend should not be discussed as though it has a single category dose. The blend name alone does not identify the component amounts, route/formulation, or ratio.

Safety Considerations

The blend inherits uncertainty from both components and adds interpretation problems of its own.

For SLU-PP-332, the main limit is translation. Mouse ERR agonism and exercise-mimetic findings do not prove human cardiometabolic benefit, endocrine safety, cancer-biology neutrality, or long-term tissue safety.

For BAM15, the main limit is mitochondrial uncoupling. BAM15 was designed as a more controllable uncoupler than older high-risk agents, but the reviewed evidence remains preclinical for metabolic use [5][6][7]. Human safety cannot be inferred from mouse body-composition outcomes.

For the fixed blend, the main limit is attribution. If adverse effects, heat intolerance, fatigue, appetite change, glucose changes, or performance changes occurred in an uncontrolled setting, the blend format would make it hard to identify which component, ratio, product quality issue, or interaction mattered.

Regulatory And Sports Context

No approved human therapeutic use or prescribing label was found for the SLU-PP-332+BAM15 blend in this refresh. Catalog pages describe research-use products rather than approved drugs [9][10][11].

For athletes, BAM15 deserves special attention. The 2026 WADA material identifies BAM15 by chemical name as an S4 metabolic-modulator example and notes supplement-market concern [8]. SLU-PP-332 was not identified by name in the same refreshed component review, but absence from an example list should not be read as permission for competitive sport.

Practical Evidence Reading

A useful assessment starts by separating four questions:

• What is SLU-PP-332 doing in the primary literature?
• What is BAM15 doing in the primary literature?
• What exact amounts and ratio does a product page list?
• Has that exact combination been tested in humans?

For this blend, the fourth answer is no. The first two answers are animal and cell evidence. The third answer varies by product page. Those facts make the blend unsuitable for claims that rely on a validated human combined protocol.

FAQ

Is there a validated human SLU-PP-332 + BAM15 protocol?

No. No combined human trial, human PK study, or validated human dosing protocol was found.

Does 250 mcg + 50 mcg mean each compound is present at both amounts?

No. It means one listed component amount plus the other listed component amount. In a 250 mcg + 50 mcg product, the active total is 300 mcg before excipients, and the components are present at different amounts.

Are all SLU-PP-332 + BAM15 blends equivalent?

No. Product pages inspected in this refresh list different component amounts and ratios, including 250 mcg + 50 mcg and much larger BAM15-dominant tablet strengths [9][10][11].

Does component evidence prove the blend works better than either compound alone?

No. The reviewed evidence supports separate component mechanisms in preclinical settings. It does not show that combining them improves outcomes or safety in humans.

Is BAM15 regulated in sport?

BAM15 is named in 2026 WADA-related material as an S4 metabolic-modulator example [8]. Competitive athletes should treat this as a serious compliance signal.

Sources & References

[1] PubChem. SLU-PP-332, CID 5338394. https://pubchem.ncbi.nlm.nih.gov/compound/5338394

[2] Billon C, Sitaula S, Banerjee S, et al. Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity. ACS Chemical Biology. 2023;18(4):756-771. https://pubmed.ncbi.nlm.nih.gov/36988910/

[3] Billon C, Schoepke E, Avdagic A, et al. A synthetic ERR agonist alleviates metabolic syndrome. Journal of Pharmacology and Experimental Therapeutics. 2024;388(2):232-240. https://pubmed.ncbi.nlm.nih.gov/37739806/

[4] PubChem. BAM15, CID 565708. https://pubchem.ncbi.nlm.nih.gov/compound/565708

[5] Kenwood BM, Weaver JL, Bajwa A, et al. Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane. Molecular Metabolism. 2014;3(2):114-123. https://pubmed.ncbi.nlm.nih.gov/24634817/

[6] Alexopoulos SJ, Chen SY, Brandon AE, et al. Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice. Nature Communications. 2020;11:2397. https://www.nature.com/articles/s41467-020-16298-2

[7] Axelrod CL, King WT, Davuluri G, et al. BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control. EMBO Molecular Medicine. 2020;12:e12088. https://pubmed.ncbi.nlm.nih.gov/32519812/

[8] World Anti-Doping Agency. 2026 Prohibited List and explanatory materials. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

[9] Nexus Laboratory. Oral Tablets catalog, SLU-PP-332 + BAM15 blend listing, inspected September 12, 2026. https://nexuslaboratory.org/shop/category/oral-tablets

[10] Disguised Alpha. SLU-PP-332 & BAM15 product page, inspected September 12, 2026. https://disguisedalpha.com/product/slu-pp-332-bam15/

[11] Pure Peptides Canada. Bam + slu Blend product page, inspected September 12, 2026. https://purepeptidescanada.com/product/bamslu-blend/

Related Guide Context

• SLU-PP-332
• BAM15
• AOD-9604
• MOTS-C
• 5-Amino-1MQ